1800505-64-9
1800505-64-9 結(jié)構(gòu)式
基本信息
化合物 T12598
化合物PZ-1,10 MM DMSO 溶液
N-(5-(叔丁基)異惡唑-3-基)-2-(4-(5-(1-甲基-1H-吡唑-4-基)-1H-苯并[D]咪唑-1-基)苯基)乙酰胺
Pz-1 >=98% (HPLC)
Benzeneacetamide, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-4-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/12/22 | HY-U00437 | 1800505-64-9 Pz-1 | 1800505-64-9 | 5mg | 650元 |
| 2025/12/22 | HY-U00437 | 1800505-64-9 Pz-1 | 1800505-64-9 | 10 mM * 1 mLin DMSO | 720元 |
| 2025/12/22 | HY-U00437 | 1800505-64-9 Pz-1 | 1800505-64-9 | 10mg | 1050元 |
常見問題列表
IC50: < 1 nM (RET and VEGFR2)
Pz-1 is a Type-II tyrosine kinase inhibitor, able to bind the DFG-out conformation of the kinase. In cell-based assays, 1.0 nM of Pz-1 strongly inhibits tyrosine phosphorylation of VEGFR2 and clinically relevant RET mutants, including those refractory to vandetanib and cabozantinib (RET V804M and RET V804L ).
Pz-1 is shown active on VEGFR2, which can block blood supply required for RET-stimulated growth. At 1.0 mg/kg/day per os, Pz-1 abrogates formation of tumors induced by RET-mutant fibroblasts and blocks phosphorylation of both RET and VEGFR2 in tumor tissue. Pz-1 features no detectable toxicity up to 100.0 mg/kg, which indicates a large therapeutic window.